

# Christoph Oing

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276647/publications.pdf>

Version: 2024-02-01

74  
papers

2,343  
citations

279487

23  
h-index

233125

45  
g-index

98  
all docs

98  
docs citations

98  
times ranked

2497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
2	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Journal of Clinical Oncology, 2019, 37, 1412-1423.	0.8	246
3	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, 1658-1686.	0.6	228
4	Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. European Urology, 2017, 71, 213-220.	0.9	161
5	Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Research, 2015, 43, 3154-3166.	6.5	105
6	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature. Journal of Urology, 2016, 195, 254-263.	0.2	99
7	Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. Scientific Reports, 2018, 8, 3947.	1.6	54
8	Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. Journal of Clinical Oncology, 2018, 36, 3381-3387.	0.8	49
9	5-Azacididine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells. International Journal of Molecular Sciences, 2019, 20, 21.	1.8	49
10	Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nature Reviews Urology, 2021, 18, 227-245.	1.9	49
11	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. ESMO Open, 2021, 6, 100058.	2.0	47
12	Anxiety and depression in long-term testicular germ cell tumor survivors. General Hospital Psychiatry, 2016, 38, 21-25.	1.2	41
13	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urologia Internationalis, 2021, 105, 169-180.	0.6	37
14	Therapeutic approaches for refractory germ cell cancer. Expert Review of Anticancer Therapy, 2018, 18, 389-397.	1.1	33
15	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Letters, 2018, 423, 60-70.	3.2	31
16	Expression of miRNA-371a-3p in seminal plasma and ejaculate is associated with sperm concentration. Andrology, 2019, 7, 469-474.	1.9	31
17	The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real-time polymerase chain reaction. Histopathology, 2021, 78, 593-606.	1.6	31
18	Bone metastases in germ cell tumor patients. Journal of Cancer Research and Clinical Oncology, 2012, 138, 947-952.	1.2	28

#	ARTICLE	IF	CITATIONS
19	The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 268.	3.5	27
20	Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1319-1325.	1.2	26
21	Investigational targeted therapies for the treatment of testicular germ cell tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1033-1043.	1.9	25
22	Platinum-refractory germ cell tumors: an update on current treatment options and developments. <i>World Journal of Urology</i> , 2017, 35, 1167-1175.	1.2	25
23	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	1.2	25
24	The impact of COVID-19 on oncology professionals' one year on: lessons learned from the ESMO Resilience Task Force survey series. <i>ESMO Open</i> , 2022, 7, 100374.	2.0	24
25	Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations. <i>Andrology</i> , 2019, 7, 487-497.	1.9	22
26	Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2011, 2, 419-423.	1.8	21
27	Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. <i>Annals of Oncology</i> , 2017, 28, 576-582.	0.6	20
28	Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. <i>Cancers</i> , 2020, 12, 2903.	1.7	20
29	Palliative treatment of germ cell cancer. <i>Cancer Treatment Reviews</i> , 2018, 71, 102-107.	3.4	19
30	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. <i>Urologia Internationalis</i> , 2021, 105, 181-191.	0.6	19
31	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , 2021, 6, 100199.	2.0	19
32	Symptom burden in long-term germ cell tumor survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 2243-2250.	1.0	18
33	The developmental origin of cancers defines basic principles of cisplatin resistance. <i>Cancer Letters</i> , 2021, 519, 199-210.	3.2	17
34	The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. <i>Oncology Research and Treatment</i> , 2018, 41, 365-369.	0.8	16
35	Current pharmacotherapy for testicular germ cell cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 837-850.	0.9	16
36	Awareness of predatory journals and open access among medical oncologists: results of an online survey. <i>ESMO Open</i> , 2019, 4, e000580.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial. <i>Oncology Research and Treatment</i> , 2016, 39, 553-556.	0.8	14
38	Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 545-560.	0.9	13
39	Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines. <i>Disease Markers</i> , 2019, 2019, 1-14.	0.6	13
40	Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 3077-3087.	0.8	13
41	First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1211-20.	1.2	11
42	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. <i>Cancers</i> , 2020, 12, 2467.	1.7	11
43	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4521-4521.	0.8	11
44	Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1979-1994.	1.2	10
45	The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 809.e19-809.e25.	0.8	10
46	Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 449-455.	1.2	10
47	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	1.9	10
48	Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. <i>Histopathology</i> , 2022, 80, 381-396.	1.6	10
49	Human chorionic gonadotropinâ€“positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	1.3	8
50	First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 923-931.	1.2	7
51	ESMO20 YO for YO: highlights on metastatic renal cell carcinomaâ€”the CheckMate-9ER trial. <i>ESMO Open</i> , 2021, 6, 100025.	2.0	7
52	Therapy of clinical stage IIA and IIB seminoma: a systematic review. <i>World Journal of Urology</i> , 2022, 40, 2829-2841.	1.2	6
53	Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer. <i>Current Opinion in Urology</i> , 2018, 28, 479-484.	0.9	5
54	TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?. <i>Clinical Cancer Research</i> , 2019, 25, 1699-1701.	3.2	4

#	ARTICLE	IF	CITATIONS
55	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World Journal of Urology, 2021, 39, 3407-3414.	1.2	4
56	Prognostic impact of LDH and HCG levels in marker-positive seminomas.. Journal of Clinical Oncology, 2020, 38, 392-392.	0.8	4
57	EP-1618: Monoubiquitinated histone H2B as a potential target in treatment resistant germ cell tumors. Radiotherapy and Oncology, 2018, 127, S871.	0.3	3
58	Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry. World Journal of Urology, 2022, 40, 373.	1.2	3
59	Nodal, pulmonary and pleural gliomatosis in a 42-year-old male with non-seminomatous testicular germ cell cancer. Histopathology, 2014, 65, 142-143.	1.6	2
60	Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World Journal of Urology, 2022, 40, 355-361.	1.2	2
61	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 825-832.	0.4	2
62	Ongoing Clinical Trials in Prostate Cancer: The STAMPEDE Trial. Oncology Research and Treatment, 2016, 39, 464-467.	0.8	1
63	Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care. Oncology Research and Treatment, 2017, 40, 609-615.	0.8	1
64	Prognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3. Annals of Oncology, 2019, 30, v363-v364.	0.6	1
65	Bone metastases in patients with relapsed/refractory germ cell tumors (GCT) undergoing first salvage chemotherapy: A retrospective analysis of a large international database.. Journal of Clinical Oncology, 2012, 30, 4597-4597.	0.8	1
66	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment. World Journal of Urology, 2022, , 1.	1.2	1
67	Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients. Bone Marrow Transplantation, 2022, , .	1.3	1
68	Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic stratification. Annals of Oncology, 2018, 29, viii325.	0.6	0
69	Editorial Comment to Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis. International Journal of Urology, 2021, 28, 847-848.	0.5	0
70	Abstract 4815: Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. , 2011, , .		0
71	Molecular profiling of testicular cancer.. Journal of Clinical Oncology, 2014, 32, 4515-4515.	0.8	0
72	Bone metastases in germ cell tumors: Results from an international data base.. Journal of Clinical Oncology, 2014, 32, 4559-4559.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Hodentumoren. , 2015, , 1-13.		0
74	Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminomaâ€”A multicenter retrospective analysis.. Journal of Clinical Oncology, 2020, 38, 420-420.	0.8	0